Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - celecoxib, quantity: 200 mg - capsule, hard - excipient ingredients: titanium dioxide; lactose monohydrate; croscarmellose sodium; povidone; sodium lauryl sulfate; magnesium stearate; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; ethanol; iron oxide yellow; shellac; strong ammonia solution - for the symptomatic treatment of osteoarthritis and rheumatoid arthritis and ankylosing spondylitis. for the treatment of primary dysmenorrhoea in adults. for the short term treatment of acute pain in adults following surgery or musculoskeletal and/or soft tissue injury.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - celecoxib, quantity: 100 mg - capsule, hard - excipient ingredients: lactose monohydrate; gelatin; sodium lauryl sulfate; magnesium stearate; croscarmellose sodium; povidone; titanium dioxide; propylene glycol; indigo carmine; butan-1-ol; isopropyl alcohol; ethanol; shellac; strong ammonia solution - for the symptomatic treatment of osteoarthritis and rheumatoid arthritis and ankylosing spondylitis. for the treatment of primary dysmenorrhoea in adults. for the short term treatment of acute pain in adults following surgery or musculoskeletal and/or soft tissue injury.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - celecoxib 100mg;   - capsule - 100 mg - active: celecoxib 100mg   excipient: croscarmellose sodium gelatin lactose monohydrate magnesium stearate povidone sodium laurilsulfate - symptomatic treatment of pain and inflammation in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. for the management of acute pain and treatment of primary dysmenorrhoea in adults. the decision to prescribe a selective cox-2 inhibitor should only be made: · if non-pharmacological interventions and simple analgesic therapies have been tried and found to lack analgesic efficacy or to have unacceptable adverse effects in the individual patient, and · after assessment of the individual patient's overall risks. as the cardiovascular risks of the selective cox-2 inhibitors may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. patients on long-term treatment should be reviewed regularly, such as every three months, with regards to efficacy, risk factors and ongoing need for treatment.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - celecoxib 200mg;   - capsule - 200 mg - active: celecoxib 200mg   excipient: croscarmellose sodium gelatin lactose monohydrate magnesium stearate povidone sodium laurilsulfate - symptomatic treatment of pain and inflammation in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. for the management of acute pain and treatment of primary dysmenorrhoea in adults. the decision to prescribe a selective cox-2 inhibitor should only be made: · if non-pharmacological interventions and simple analgesic therapies have been tried and found to lack analgesic efficacy or to have unacceptable adverse effects in the individual patient, and · after assessment of the individual patient's overall risks. as the cardiovascular risks of the selective cox-2 inhibitors may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. patients on long-term treatment should be reviewed regularly, such as every three months, with regards to efficacy, risk factors and ongoing need for treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - celecoxib, quantity: 100 mg - capsule, hard - excipient ingredients: croscarmellose sodium; lactose monohydrate; povidone; magnesium stearate; colloidal anhydrous silica; sodium lauryl sulfate; titanium dioxide; indigo carmine; purified water; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.,for the treatment of primary dysmenorrhoea in adults.,for the short-term treatment of acute pain in adults following surgery or musculoskeletal and/or soft tissue injury.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - celecoxib, quantity: 200 mg - capsule, hard - excipient ingredients: croscarmellose sodium; magnesium stearate; povidone; lactose monohydrate; sodium lauryl sulfate; colloidal anhydrous silica; titanium dioxide; purified water; iron oxide yellow; iron oxide red; gelatin; iron oxide black; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; ethanol; shellac; sulfuric acid - for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.,for the treatment of primary dysmenorrhoea in adults.,for the short-term treatment of acute pain in adults following surgery or musculoskeletal and/or soft tissue injury.

Israel - English - Ministry of Health

megapharm ltd - iloperidone - tablets - iloperidone 1 mg - iloperidone - iloperidone - fanapt is an atypical antipsychotic agent indicated for the treatment of schizophrenia in adults.

Israel - English - Ministry of Health

megapharm ltd - iloperidone - tablets - iloperidone 2 mg - iloperidone - iloperidone - fanapt is an atypical antipsychotic agent indicated for the treatment of schizophrenia in adults.

Israel - English - Ministry of Health

megapharm ltd - iloperidone - tablets - iloperidone 4 mg - iloperidone - iloperidone - fanapt is an atypical antipsychotic agent indicated for the treatment of schizophrenia in adults.

Israel - English - Ministry of Health

megapharm ltd - iloperidone - tablets - iloperidone 6 mg - iloperidone - iloperidone - fanapt is an atypical antipsychotic agent indicated for the treatment of schizophrenia in adults.